Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec departure
confidence 95%
filed 2026-07-22
Item 5.02
Kenneth S. Booth resigned from the board of directors of Credit Acceptance Corporation on July 21, 2026. The filing explicitly states his departure and notes that the Board size was reduced from six to five directors in connection with his resignation. This is a clear director departure disclosure under Item 5.02, and board composition changes are material to investors assessing corporate governance.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-22
Item 5.02
Jonathan Robins, Chief Technology Officer, notified the Company on July 16, 2026 of his decision to separate from employment effective July 18, 2026, with final termination on October 16, 2026. While the MOU includes compensatory elements (continued healthcare benefits and COBRA coverage), the principal disclosed action is the departure of a named executive officer from a key technical leadership role. The separation agreement and release of claims are ancillary to the core event of his departure.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-22
Item 5.02
Ian T. Clark resigned from the Board of Directors of Corvus Pharmaceuticals, effective July 22, 2026, after over nine years of service. The disclosure centers on a director's departure, making this a clear exec_departure event. Board changes are material to investors assessing governance and leadership continuity.
View raw filing on EDGAR →
8-K
Exec departure
confidence 85%
filed 2026-07-22
Item 5.02
All members of NSA's board of trustees and all officers ceased their positions effective at the merger closing. Named executive officers' employment was terminated without cause, triggering severance obligations under existing employment agreements.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-22
Item 5.02
R. Colby Slaughter, Senior Vice President, General Counsel and Corporate Secretary, notified the Company of his resignation effective August 7, 2026. The departure of a named executive officer holding senior legal and governance responsibilities is material to investors' assessment of the registrant's leadership and operational continuity.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-22
Item 5.02
Steven Ciardiello, Chief Accounting Officer, notified the Company on July 16, 2026 of his resignation effective August 28, 2026. The departure of a CAO is material to investors as it affects financial reporting oversight and internal controls, with the Company conducting a search for a successor.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-22
Item 5.02
Tracy Willis, Vice President and Chief Accounting Officer, notified the Company of her intention to resign effective August 6, 2026. While the filing also discloses that James Volk will assume her accounting responsibilities, the principal disclosed action is Willis's departure from an officer position. The departure of a Chief Accounting Officer is material to investors as it affects the registrant's financial reporting oversight and internal controls.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-22
Item 5.02
Douglas Kling, the Company's Chief Operating Officer, notified the company on July 16, 2026 of his resignation effective August 14, 2026 to join another biotech company as CEO. This is a clear executive departure of a named officer. While the filing mentions anticipated separation and advisor agreements, the principal disclosed action is Kling's departure from his COO role, making exec_departure the most salient classification.
View raw filing on EDGAR →
8-K
Exec departure
confidence 85%
filed 2026-07-22
Item 5.02
The principal disclosed action is the termination of Geoffrey Hitchcock, Chief Revenue Officer, effective July 23, 2026, following a for-cause determination by the Board under his Employment Agreement. While the filing also discloses a subsequent civil complaint filed by Mr. Hitchcock (Item 8.01), the core Item 5.02 event is the executive departure itself. The for-cause termination and denial of severance benefits are material to investors assessing leadership stability and potential litigation risk.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-07-22
Item 5.02
J. Ted Nissen retired as Executive Vice President and Chief Banking Officer of the Company and President and CEO of the Bank, effective December 31, 2026, after 31 years with the organization. His departure triggers a leadership restructuring in which the CEO and President role will be split.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-22
Item 5.02
Casey Tansey, a Board member of 18+ years and early venture investor who led Inspire's Series A financing in 2007, notified the Company on July 16, 2026 of his decision to retire from the Board effective July 30, 2026. The Item 5.02 disclosure centers on his departure from the Board and decision not to stand for re-election, with no compensatory arrangements or new appointments disclosed. This is a material departure of a long-tenured director with significant historical influence on the company.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-22
Item 5.02
Michael D. Garrison, Executive Vice President and President of the Medical Essentials and BioPharma Systems segments, informed BD of his intention to retire effective October 2, 2026, after more than 20 years with the company. The filing also discloses an organizational restructuring whereby BioPharma Systems will report directly to the CEO following his departure.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-07-22
Item 5.02
Mingxiao (Gary) Guo, Senior Vice President and Chief Global Integrated Supply Chain Officer, is departing Trane Technologies effective August 1, 2026. The principal disclosed action is a named executive officer leaving the company. While the filing mentions a Separation Agreement and foregoing of clawback provisions, the core event is the departure itself, making exec_departure the most salient classification.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-21
Item 5.02
Matthew A. Hunton, Executive Vice President and President of Kemper Auto, is departing effective August 3, 2026, following a termination by the Company without cause. While severance benefits are mentioned, the principal disclosed action is the departure of a named executive officer from a significant operational role. This is material to investors as it affects leadership of a major business segment.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-21
Item 5.02
Curtis D. Hodgson, Executive Chairman and Board member of Legacy Housing Corporation, notified the Board on July 17, 2026 of his retirement effective July 21, 2026. The disclosure centers on his departure from executive and board positions, making this a clear executive departure event. The retirement of a company's Executive Chairman is material to investors as it represents a significant leadership change.
View raw filing on EDGAR →
8-K
Exec departure
confidence 85%
filed 2026-07-21
Item 5.02
Kara Wilson, a director of Paychex, notified the Board on July 16, 2026 of her decision not to stand for re-election at the 2026 annual meeting, resulting in her departure from the Board. Although the departure is effective at the Annual Meeting (a future date), the principal disclosed action is a director's decision to leave office. The filing explicitly states the decision was not due to disagreement, and the Board's consequent reduction in size from 11 to 10 directors is a direct consequence of this departure.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-07-21
Jack Mallers resigned as CEO and director effective July 20, 2026, with a separation agreement providing cash payments and vested equity. While the filing also discloses Raphael Zagury's appointment as CEO, the principal disclosed action centers on Mallers' departure—the triggering event that necessitated the leadership transition. The departure is material to a reasonable investor assessing the registrant's leadership continuity.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-07-21
Mr. Niels Brix, an independent director since December 2021, resigned from the board and all committees effective immediately on July 7, 2026. The resignation was triggered by a lapse in the Company's directors and officers (D&O) insurance coverage, which the Company has since restored. This is a clear executive departure under Item 5.02, material because it involves loss of board representation and reflects a governance control failure (lapsed insurance).
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-07-21
Item 5.02
All seven board members resigned effective upon Form 15 filing, and four key executives—CEO Stephen From, President Adam Sachs, CTO Sammy Khalifa, and Chief Medical Officer Dr. Barry Greene—were terminated effective July 21, 2026, in connection with the company's liquidation.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-21
Item 5.02
Lisa Bollinger, MD, Chief Medical Officer, resigned from her position effective immediately on July 19, 2026. The disclosure centers on the departure of a named executive officer from a key leadership role overseeing clinical and regulatory functions at a therapeutics company. While the company states it does not anticipate impact on clinical timelines, the departure of a CMO is material to investors assessing the company's development capabilities and execution risk.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-21
Item 5.02
Yakov Baranes, a board member of Charging Robotics Inc., tendered his resignation from the Board effective immediately on July 21, 2026. This is a clear departure of a director, which is material to investors as it affects board composition and governance. The disclosure explicitly states the resignation was for personal reasons and not due to disagreement, which is standard boilerplate but does not diminish the materiality of the board change itself.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-21
Item 8.01
Dr. Lynne Fahey McGrath, a director since the Company's June 2021 IPO, passed away on July 20, 2026. This constitutes a departure of a director from the Board due to death. The disclosure is material as it affects the composition of the Board and the loss of a long-serving director with significant biopharmaceutical expertise, which would affect a reasonable investor's assessment of the Company's governance and leadership.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-21
Item 5.02
Lynne M. Neel, Senior Executive Vice President overseeing critical functions (loan operations, deposit operations, electronic banking, and investor relations) at Embassy Bancorp, informed the company on July 16, 2026 of her intention to retire effective April 2, 2027. This is a departure of a named executive officer with significant operational responsibilities, disclosed under Item 5.02. The filing explicitly states her retirement is not due to disagreement, confirming it is a planned departure rather than a termination or dispute.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-21
Dr. Gregory M. Sullivan, Chief Medical Officer, informed the Company on July 20, 2026 that he will retire from his role effective August 20, 2026. This is a clear executive departure disclosed under Item 5.02, representing the departure of a named officer from the Company.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-07-21
Item 5.02
Lori Gustafson, Executive Vice President and Chief Brand and Digital Officer, is separating from Marriott Vacations Worldwide effective July 31, 2026, due to elimination of her position in an internal reorganization. While the disclosure includes severance details ($1,425,000 plus potential performance payment), the principal disclosed action is her departure from the company. The event is material as it involves a named executive officer's separation and would affect investor assessment of leadership continuity.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-07-21
Item 5.02
Girish Venkatachaliah, Chief Technology Officer, is departing the Company effective August 1, 2026. While the disclosure also includes severance compensation details (cash severance of $766,063 and continued equity vesting through April 30, 2027), the principal disclosed action is the executive's departure. The severance and consulting arrangements are ancillary to the core event of the CTO leaving the organization.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-20
Item 5.02
William R. Nelson resigned from his position as President of the Republic Processing Group (RPG) effective August 28, 2026, to accept an executive opportunity elsewhere. While the filing also mentions Brent Shuman assuming the interim role, the principal disclosed action is Nelson's departure. The resignation of a division president is material to investors assessing management stability and operational continuity.
View raw filing on EDGAR →
6-K
Exec departure
confidence 92%
filed 2026-07-20
Adar Segal is stepping down from his position as Head of Automotive at Valens Semiconductor Ltd., with employment expected to terminate following a 180-day notice period. This is a clear executive departure disclosure. While the Head of Automotive may not be a named executive officer in the traditional sense, the formal announcement of a leadership departure in a 6-K filing indicates materiality to investors assessing the company's operational continuity and automotive segment leadership.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-07-20
Item 5.02
Jack Cho resigned from the Board on July 16, 2026, having served as chair of the Audit Committee and member of the Compensation Committee. While the filing also discloses appointments to fill the vacancies (Gonzalez, Gan, and Chu), the principal disclosed action centers on Cho's departure from the Board. The resignation is material as it affects board composition and audit committee leadership, though the non-disputed nature and immediate replacement mitigate some concern.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-07-17
Item 5.02
The filing discloses two executive departures: Richard Lowenthal's resignation from the Board of Directors effective immediately on July 15, 2026, and Sarina Tanimoto, M.D. (Chief Medical Officer), ceasing employment under a termination without cause on the same date. While severance and compensatory arrangements are mentioned, the principal disclosed action centers on these two individuals leaving their roles. The departure of a CMO is material to a pharmaceutical company's operations and investor assessment.
View raw filing on EDGAR →
8-K
Exec departure
confidence 85%
filed 2026-07-17
Item 5.02
The filing discloses two significant executive departures: Ajay Kumar Dhadha resigned as Chairman and Director effective June 30, 2026, and Guy Ofir resigned as Chief Financial Officer, General Counsel, and Director effective July 16, 2026. While the section also mentions the appointment of Uri Tadelis as CFO, the principal disclosed actions center on the departures of two senior officers, including the CFO and Board Chairman. Both resignations are stated to be voluntary and without disagreement with the Company.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-17
Item 5.02
Nancy Lipson announced her resignation from the Board of Directors of Frontier Group Holdings, Inc., effective July 15, 2026, to pursue another business opportunity. This is a clear director departure disclosure under Item 5.02, with no indication of disagreement or controversy. Director changes are material to investors assessing governance and board composition.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-17
Item 5.02
Alejandro Araujo resigned from the Company's Board of Directors effective immediately on June 4, 2026, and also resigned from all Board committees. This is a clear departure of a director. While the filing notes no disagreement with the Company, the departure itself is the principal disclosed action and is material to investors' assessment of board composition and governance.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-07-16
Item 5.02
Chief Financial Officer Glenn Reicin departed effective July 16, 2026 to pursue other career opportunities, with Stephen Mollichella appointed as Interim Principal Financial Officer.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-07-16
Item 5.02
Dr. Richard Glickman resigned as director and chairman of the Board effective immediately on July 15, 2026, after serving in that role for over 14 years. Michael Heffernan assumes the chairman role.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-16
Item 5.02
Seven directors (Andrew R. Cichocki, Paula M. Harris, Linda A. Harty, Paul E. Mahoney, David M. Sagehorn, Spencer S. Stiles, and Roger A. Strauch) and three executive officers (Gerald F. Vinci, Joseph R. Brinkman, and Herbert G. Hotchkiss) departed effective upon consummation of the merger, while one officer (Joseph A. Belling) continued.
View raw filing on EDGAR →
6-K
Exec departure
confidence 75%
filed 2026-07-16
EX-99.1
Tamir Fayerman, a Board member and Audit Committee Chairman, resigned effective July 16, 2026 for personal reasons. While the press release also announces the appointment of Asaf Itzhaik as the new Audit Committee Chairman and Ohad Melnik-Marom as a new Board member, the principal disclosed action is Fayerman's departure from the Board and all committees. The loss of an Audit Committee Chairman is material to investors assessing governance and financial oversight.
View raw filing on EDGAR →
6-K
Exec departure
confidence 95%
filed 2026-07-16
The Board of Directors meeting minutes disclose the resignation of Mr. Nitin Prabhu from his role as Member of the Board of Directors, effective July 28, 2026. This is a departure of a director, which is a material governance event that would affect a reasonable investor's assessment of the company's leadership composition and continuity.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-07-16
The filing discloses the departure of Lance Alstodt (President, CEO, and Chairman) and Robert Kristal (CFO) on July 13, 2026, both asserting "Good Reason" resignations tied to a claimed Change in Control. While the Board disputes the validity of these claims and has reserved all rights, the departures of the CEO and CFO are material events that would affect a reasonable investor's assessment of the registrant. The filing also includes amendments to executive employment agreements narrowing Change in Control triggers and the appointment of interim leadership, but the principal disclosed action centers on the departure of two key executives.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-16
Item 5.02
Shlomo Dovrat resigned as a member of the Board of Directors of Unity Software Inc., effective July 24, 2026. The disclosure centers on a director's departure, which is a material governance event affecting the composition of the board and would be relevant to investors assessing the company's leadership and governance structure.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-16
Item 5.02
Jen Porter, Chief Marketing and eCommerce Officer, separated from the Company effective July 15, 2026, in connection with organizational restructuring. While the disclosure mentions severance benefits contingent on a release of claims, the principal disclosed action is the departure of a named executive officer, making this an exec_departure event. The separation is material as it involves a C-suite executive and reflects strategic organizational changes.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-15
Item 5.02
Sam Martin, Senior Vice President and Chief Financial Officer, notified the Company of his plans to retire effective March 31, 2027. The principal disclosed action is the departure of a named executive officer (CFO) from the Company, with a clear effective date and transition plan. This is a material event affecting investor assessment of the registrant's leadership and financial management continuity.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-15
Item 8.01
Ian Ratcliffe, an independent director on the Board since February 2024, passed away on July 5, 2026. While the filing also mentions a board size reduction and appointment of Nicholas Naclerio to the Audit Committee, the principal disclosed event is the departure of a director due to death. This is material as it affects board composition and governance structure.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-07-15
Item 5.02
John C. Roche, the current President and CEO and Board member, is retiring effective December 31, 2026. While the filing also announces Richard W. Lavey's appointment as CEO-Elect, the primary disclosed action centers on Roche's departure after a 40-year insurance career and 20 years with the company. The retirement of a sitting CEO is material to investors assessing leadership continuity and company direction.
View raw filing on EDGAR →
6-K
Exec departure
confidence 75%
filed 2026-07-15
Mr. Shibin Yu resigned as Chief Financial Officer and director of ATIF Holdings on July 14, 2026, effective immediately. While the filing also discloses the appointment of Dr. Kamran Khan as interim CFO, the principal disclosed action is Yu's departure from both the CFO and board positions. The resignation of a CFO is material to investors' assessment of the company's financial leadership and governance.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-15
Mark Murray resigned from the Board of Directors effective July 13, 2026, for personal reasons with no disagreement with the Company. Item 5.02(b) explicitly governs director departures. While the press release emphasizes Murray's valued contributions and the amicable nature of his departure, the core disclosed event is a director's resignation, making this an exec_departure classification. The filing is material as director changes affect governance and investor assessment of the company.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-15
Jeffrey Millard, Chief Operating Officer, resigned effective July 10, 2026. Item 5.02 discloses the departure of a named officer, making this a clear executive departure event. The COO role is material to the company's operations and governance.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-15
Item 5.02
David Weinstein resigned from his position as a member of the Board of Directors, effective July 31, 2026. Weinstein was a founding board member and former CEO who played a significant role during the company's transition to public markets.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-07-14
Item 5.02
Nicholas J. Brazis, Executive Vice President and Chief Financial Officer, resigned effective July 10, 2026 to pursue an opportunity at a private company. Robert P. Fishman was appointed as Interim CFO.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-07-14
Item 5.02
Valerie Greer, Executive Vice President and Chief Commercial Officer, has provided notice of her intent to retire effective February 19, 2027, after nearly four decades in financial services and six years with Bread Financial. The retirement agreement includes severance and benefits, and her departure is material to investors assessing leadership continuity.
View raw filing on EDGAR →